{"id":70260,"date":"2026-07-20T12:09:45","date_gmt":"2026-07-20T04:09:45","guid":{"rendered":"https:\/\/flcube.com\/?p=70260"},"modified":"2026-07-20T12:09:47","modified_gmt":"2026-07-20T04:09:47","slug":"gsk-reports-mixed-phase-iii-results-for-camlipixant-in-refractory-chronic-cough-calm-1-trial-meets-primary-endpoint-while-calm-2-falls-short","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70260","title":{"rendered":"GSK Reports Mixed Phase III Results for Camlipixant in Refractory Chronic Cough: CALM-1 Trial Meets Primary Endpoint While CALM-2 Falls Short"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>GlaxoSmithKline plc (GSK)<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/GSK:NYSE\">NYSE: GSK<\/a>) announced mixed results from the <strong>CALM-1 and CALM-2 Phase III clinical trials<\/strong> evaluating <strong>camlipixant<\/strong>, a <strong>P2X3 receptor antagonist<\/strong>, in adult patients with <strong>refractory chronic cough (RCC)<\/strong>. While <strong>CALM-1 met its primary endpoint<\/strong> with the 50mg twice-daily dose showing statistically significant reduction in 24-hour cough frequency versus placebo at week 12, <strong>CALM-2 failed to achieve statistical significance<\/strong> for the same dose and endpoint at week 24.<\/p>\n\n\n\n<h2 id=\"h-clinical-trial-outcomes-summary\" class=\"wp-block-heading\">Clinical Trial Outcomes Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Trial<\/th><th>Dose Regimen<\/th><th>Primary Endpoint<\/th><th>Result<\/th><th>Timepoint<\/th><\/tr><\/thead><tbody><tr><td><strong>CALM-1<\/strong><\/td><td>Camlipixant 50mg BID<\/td><td>24-hour cough frequency reduction vs placebo<\/td><td><strong>Met<\/strong> (statistically significant)<\/td><td>Week 12<\/td><\/tr><tr><td><strong>CALM-2<\/strong><\/td><td>Camlipixant 50mg BID<\/td><td>24-hour cough frequency reduction vs placebo<\/td><td><strong>Not met<\/strong> (not statistically significant)<\/td><td>Week 24<\/td><\/tr><tr><td><strong>Both Trials<\/strong><\/td><td>Camlipixant 25mg BID<\/td><td>24-hour cough frequency reduction vs placebo<\/td><td><strong>Not met<\/strong> (not statistically significant)<\/td><td>Weeks 12\/24<\/td><\/tr><tr><td><strong>Both Trials<\/strong><\/td><td>Both doses<\/td><td>Chronic Cough Diary (CCD) secondary endpoints<\/td><td><strong>Not met<\/strong> (failed to reach target thresholds)<\/td><td>Various<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-development-context\" class=\"wp-block-heading\">Drug Profile &amp; Development Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Camlipixant \u2013 selective P2X3 receptor antagonist<\/li>\n\n\n\n<li><strong>Indication:<\/strong> Refractory chronic cough (RCC) \u2013 persistent cough lasting >8 weeks despite standard treatment<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Blocks P2X3 receptors involved in cough reflex hypersensitivity<\/li>\n\n\n\n<li><strong>Development Stage:<\/strong> Phase III (pivotal trials completed)<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Part of emerging class of P2X3 antagonists targeting chronic cough, following precedents like gefapixant<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-safety-profile-assessment\" class=\"wp-block-heading\">Safety Profile Assessment<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Camlipixant<\/th><th>Placebo<\/th><th>Assessment<\/th><\/tr><\/thead><tbody><tr><td><strong>Overall AE Incidence<\/strong><\/td><td>Similar<\/td><td>Similar<\/td><td>Favorable safety profile<\/td><\/tr><tr><td><strong>Treatment-Related AE Severity<\/strong><\/td><td>Similar<\/td><td>Similar<\/td><td>No significant safety concerns<\/td><\/tr><tr><td><strong>Discontinuation Rate<\/strong><\/td><td>Not disclosed<\/td><td>Not disclosed<\/td><td>Requires further analysis<\/td><\/tr><tr><td><strong>Taste-Related AEs<\/strong><\/td><td>Not specifically reported<\/td><td>Not specifically reported<\/td><td>Key differentiator vs other P2X3 antagonists<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-implications-amp-next-steps\" class=\"wp-block-heading\">Strategic Implications &amp; Next Steps<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Regulatory Pathway:<\/strong> Mixed results create uncertainty for regulatory submissions; GSK may need to conduct additional analyses or trials<\/li>\n\n\n\n<li><strong>Commercial Viability:<\/strong> Failure of key secondary endpoints (CCD measures) and inconsistent primary endpoint results across trials weaken value proposition<\/li>\n\n\n\n<li><strong>Market Opportunity:<\/strong> Refractory chronic cough affects an estimated 5-10 million adults in major markets, representing significant unmet need<\/li>\n\n\n\n<li><strong>Competitive Positioning:<\/strong> Results less compelling than earlier P2X3 antagonist data, potentially limiting market differentiation<\/li>\n\n\n\n<li><strong>Investment Impact:<\/strong> Likely negative near-term impact on GSK&#8217;s respiratory pipeline valuation; company may reassess development priorities<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical trial results, regulatory pathways, and commercial prospects for camlipixant. Actual outcomes may differ due to risks including regulatory decisions, competitive dynamics, and further data analysis.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><br><\/p>\n","protected":false},"excerpt":{"rendered":"<p>GlaxoSmithKline plc (GSK) (NYSE: GSK) announced mixed results from the CALM-1 and CALM-2 Phase III&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[17,278,184,914],"class_list":["post-70260","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-results","tag-glaxosmithkline","tag-gsk","tag-nyse-gsk"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>GSK Reports Mixed Phase III Results for Camlipixant in Refractory Chronic Cough: CALM-1 Trial Meets Primary Endpoint While CALM-2 Falls Short - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"GlaxoSmithKline plc (GSK) (NYSE: GSK) announced mixed results from the CALM-1 and CALM-2 Phase III clinical trials evaluating camlipixant, a P2X3 receptor antagonist, in adult patients with refractory chronic cough (RCC). While CALM-1 met its primary endpoint with the 50mg twice-daily dose showing statistically significant reduction in 24-hour cough frequency versus placebo at week 12, CALM-2 failed to achieve statistical significance for the same dose and endpoint at week 24.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70260\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GSK Reports Mixed Phase III Results for Camlipixant in Refractory Chronic Cough: CALM-1 Trial Meets Primary Endpoint While CALM-2 Falls Short\" \/>\n<meta property=\"og:description\" content=\"GlaxoSmithKline plc (GSK) (NYSE: GSK) announced mixed results from the CALM-1 and CALM-2 Phase III clinical trials evaluating camlipixant, a P2X3 receptor antagonist, in adult patients with refractory chronic cough (RCC). While CALM-1 met its primary endpoint with the 50mg twice-daily dose showing statistically significant reduction in 24-hour cough frequency versus placebo at week 12, CALM-2 failed to achieve statistical significance for the same dose and endpoint at week 24.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70260\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-20T04:09:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-20T04:09:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70260#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70260\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GSK Reports Mixed Phase III Results for Camlipixant in Refractory Chronic Cough: CALM-1 Trial Meets Primary Endpoint While CALM-2 Falls Short\",\"datePublished\":\"2026-07-20T04:09:45+00:00\",\"dateModified\":\"2026-07-20T04:09:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70260\"},\"wordCount\":403,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial results\",\"GlaxoSmithKline\",\"GSK\",\"NYSE: GSK\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70260#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70260\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70260\",\"name\":\"GSK Reports Mixed Phase III Results for Camlipixant in Refractory Chronic Cough: CALM-1 Trial Meets Primary Endpoint While CALM-2 Falls Short - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-20T04:09:45+00:00\",\"dateModified\":\"2026-07-20T04:09:47+00:00\",\"description\":\"GlaxoSmithKline plc (GSK) (NYSE: GSK) announced mixed results from the CALM-1 and CALM-2 Phase III clinical trials evaluating camlipixant, a P2X3 receptor antagonist, in adult patients with refractory chronic cough (RCC). While CALM-1 met its primary endpoint with the 50mg twice-daily dose showing statistically significant reduction in 24-hour cough frequency versus placebo at week 12, CALM-2 failed to achieve statistical significance for the same dose and endpoint at week 24.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70260#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70260\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70260#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GSK Reports Mixed Phase III Results for Camlipixant in Refractory Chronic Cough: CALM-1 Trial Meets Primary Endpoint While CALM-2 Falls Short\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GSK Reports Mixed Phase III Results for Camlipixant in Refractory Chronic Cough: CALM-1 Trial Meets Primary Endpoint While CALM-2 Falls Short - Insight, China&#039;s Pharmaceutical Industry","description":"GlaxoSmithKline plc (GSK) (NYSE: GSK) announced mixed results from the CALM-1 and CALM-2 Phase III clinical trials evaluating camlipixant, a P2X3 receptor antagonist, in adult patients with refractory chronic cough (RCC). While CALM-1 met its primary endpoint with the 50mg twice-daily dose showing statistically significant reduction in 24-hour cough frequency versus placebo at week 12, CALM-2 failed to achieve statistical significance for the same dose and endpoint at week 24.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70260","og_locale":"en_US","og_type":"article","og_title":"GSK Reports Mixed Phase III Results for Camlipixant in Refractory Chronic Cough: CALM-1 Trial Meets Primary Endpoint While CALM-2 Falls Short","og_description":"GlaxoSmithKline plc (GSK) (NYSE: GSK) announced mixed results from the CALM-1 and CALM-2 Phase III clinical trials evaluating camlipixant, a P2X3 receptor antagonist, in adult patients with refractory chronic cough (RCC). While CALM-1 met its primary endpoint with the 50mg twice-daily dose showing statistically significant reduction in 24-hour cough frequency versus placebo at week 12, CALM-2 failed to achieve statistical significance for the same dose and endpoint at week 24.","og_url":"https:\/\/flcube.com\/?p=70260","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-20T04:09:45+00:00","article_modified_time":"2026-07-20T04:09:47+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70260#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70260"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GSK Reports Mixed Phase III Results for Camlipixant in Refractory Chronic Cough: CALM-1 Trial Meets Primary Endpoint While CALM-2 Falls Short","datePublished":"2026-07-20T04:09:45+00:00","dateModified":"2026-07-20T04:09:47+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70260"},"wordCount":403,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial results","GlaxoSmithKline","GSK","NYSE: GSK"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70260#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70260","url":"https:\/\/flcube.com\/?p=70260","name":"GSK Reports Mixed Phase III Results for Camlipixant in Refractory Chronic Cough: CALM-1 Trial Meets Primary Endpoint While CALM-2 Falls Short - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-20T04:09:45+00:00","dateModified":"2026-07-20T04:09:47+00:00","description":"GlaxoSmithKline plc (GSK) (NYSE: GSK) announced mixed results from the CALM-1 and CALM-2 Phase III clinical trials evaluating camlipixant, a P2X3 receptor antagonist, in adult patients with refractory chronic cough (RCC). While CALM-1 met its primary endpoint with the 50mg twice-daily dose showing statistically significant reduction in 24-hour cough frequency versus placebo at week 12, CALM-2 failed to achieve statistical significance for the same dose and endpoint at week 24.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70260#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70260"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70260#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GSK Reports Mixed Phase III Results for Camlipixant in Refractory Chronic Cough: CALM-1 Trial Meets Primary Endpoint While CALM-2 Falls Short"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70260","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70260"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70260\/revisions"}],"predecessor-version":[{"id":70261,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70260\/revisions\/70261"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70260"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70260"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70260"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}